These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32592729)

  • 1. Improved efficacy of doxorubicin delivery by a novel dual-ligand-modified liposome in hepatocellular carcinoma.
    Li X; Diao W; Xue H; Wu F; Wang W; Jiang B; Bai J; Lian B; Feng W; Sun T; Yu W; Wu J; Qu M; Wang Y; Gao Z
    Cancer Lett; 2020 Oct; 489():163-173. PubMed ID: 32592729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual-Ligand-Functionalized Liposomes Based on Glycyrrhetinic Acid and cRGD for Hepatocellular Carcinoma Targeting and Therapy.
    Qiu M; Wang J; Bai J; Li X; Tian C; Liu Z; Zheng C; Clark AR; Cheng X; Liao X; Wu S; Lee RJ; Zhou X
    Mol Pharm; 2023 Apr; 20(4):1951-1963. PubMed ID: 36952242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lactoferrin-modified PEGylated liposomes loaded with doxorubicin for targeting delivery to hepatocellular carcinoma.
    Wei M; Guo X; Tu L; Zou Q; Li Q; Tang C; Chen B; Xu Y; Wu C
    Int J Nanomedicine; 2015; 10():5123-37. PubMed ID: 26316745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocellular carcinoma dually-targeted nanoparticles for reduction triggered intracellular delivery of doxorubicin.
    Mezghrani O; Tang Y; Ke X; Chen Y; Hu D; Tu J; Zhao L; Bourkaib N
    Int J Pharm; 2015 Jan; 478(2):553-68. PubMed ID: 25455765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced doxorubicin delivery to hepatocellular carcinoma cells via CD147 antibody-conjugated immunoliposomes.
    Wang J; Wu Z; Pan G; Ni J; Xie F; Jiang B; Wei L; Gao J; Zhou W
    Nanomedicine; 2018 Aug; 14(6):1949-1961. PubMed ID: 29045824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycyrrhetinic acid-conjugated polymeric prodrug micelles co-delivered with doxorubicin as combination therapy treatment for liver cancer.
    Yang T; Lan Y; Cao M; Ma X; Cao A; Sun Y; Yang J; Li L; Liu Y
    Colloids Surf B Biointerfaces; 2019 Mar; 175():106-115. PubMed ID: 30529816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumor therapy of glycyrrhetinic acid targeted liposome co-delivery of doxorubicin and berberine for hepatocellular carcinoma.
    Xu N; Wu J; Wang W; Sun S; Sun M; Bian Y; Zhang H; Liu S; Yu G
    Drug Deliv Transl Res; 2024 Sep; 14(9):2386-2402. PubMed ID: 38236508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer.
    Deshpande P; Jhaveri A; Pattni B; Biswas S; Torchilin V
    Drug Deliv; 2018 Nov; 25(1):517-532. PubMed ID: 29433357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocellular Carcinoma Targeting and Pharmacodynamics of Paclitaxel Nanoliposomes Modified by Glycyrrhetinic Acid and Ferric Tetroxide.
    Zhao L; Liang L; Guo M; Li M; Yu X; Wang Y; Wang Y
    Curr Top Med Chem; 2021 Oct; 21(14):1268-1284. PubMed ID: 34620053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained liver targeting and improved antiproliferative effect of doxorubicin liposomes modified with galactosylated lipid and PEG-lipid.
    Wang S; Xu H; Xu J; Zhang Y; Liu Y; Deng YH; Chen D
    AAPS PharmSciTech; 2010 Jun; 11(2):870-7. PubMed ID: 20490957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma.
    Zhou X; Zhang M; Yung B; Li H; Zhou C; Lee LJ; Lee RJ
    Int J Nanomedicine; 2012; 7():5465-74. PubMed ID: 23093902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local targeted therapy of liver metastasis from colon cancer by galactosylated liposome encapsulated with doxorubicin.
    Zhao C; Feng Q; Dou Z; Yuan W; Sui C; Zhang X; Xia G; Sun H; Ma J
    PLoS One; 2013; 8(9):e73860. PubMed ID: 24040096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insight into the role of dual-ligand modification in low molecular weight heparin based nanocarrier for targeted delivery of doxorubicin.
    Du H; Liu M; Yu A; Ji J; Zhai G
    Int J Pharm; 2017 May; 523(1):427-438. PubMed ID: 28359815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of localized ultrasound-targeted microbubble destruction with doxorubicin liposomes in H22 mouse hepatocellular carcinoma model.
    Zhu F; Jiang Y; Luo F; Li P
    J Drug Target; 2015 May; 23(4):323-34. PubMed ID: 25609362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.
    Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R
    J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocellular carcinoma-targeted effect of configurations and groups of glycyrrhetinic acid by evaluation of its derivative-modified liposomes.
    Sun Y; Dai C; Yin M; Lu J; Hu H; Chen D
    Int J Nanomedicine; 2018; 13():1621-1632. PubMed ID: 29588589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy.
    Qi WW; Yu HY; Guo H; Lou J; Wang ZM; Liu P; Sapin-Minet A; Maincent P; Hong XC; Hu XM; Xiao YL
    Mol Pharm; 2015 Mar; 12(3):675-83. PubMed ID: 25584860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomes for targeting hepatocellular carcinoma: use of conjugated arabinogalactan as targeting ligand.
    Shah SM; Goel PN; Jain AS; Pathak PO; Padhye SG; Govindarajan S; Ghosh SS; Chaudhari PR; Gude RP; Gopal V; Nagarsenker MS
    Int J Pharm; 2014 Dec; 477(1-2):128-39. PubMed ID: 25311181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-101 and doxorubicin codelivered by liposomes suppressing malignant properties of hepatocellular carcinoma.
    Xu F; Liao JZ; Xiang GY; Zhao PX; Ye F; Zhao Q; He XX
    Cancer Med; 2017 Mar; 6(3):651-661. PubMed ID: 28135055
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Diril M; Özdokur KV; Yıldırım Y; Karasulu HY
    Pharm Dev Technol; 2023 Dec; 28(10):915-927. PubMed ID: 37921920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.